Physician

Paul G Sutej, MD

According to 2025 Medicare claims, Paul Sutej, MD (NPI: 1053353052) practices rheumatology in the Atlanta-Sandy Springs-Roswell, GA market, with the plurality of this provider's patient population coming from Fulton, GA. This provider's primary affiliated billing organization is SOUTHEASTERN RHEUMATOLOGY ALLIANCE (NPI: 1114795663; TIN: 933460719) and primary practice location at 30342-1623. Sutej is affiliated with the Southeastern Health Partners (ACO ID: A3325) and TC2, LLC (ACO ID: A3365), participating under the MSSP model.

Sutej's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 923 traditional Medicare patients, billed 199,832 HCPCS/CPT codes, and received $2,752,943 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 2,047 prescription claims across 525 beneficiaries totaling $1,401,753 in drug costs, led by Xeljanz Xr (Tofacitinib Citrate). Open Payments data shows 128 records totaling $19,305. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,650,602 and ending at $1,401,753. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,181	99,265	$2,366,208
2016	1,117	120,318	$2,492,511
2017	1,062	147,390	$2,818,122
2018	997	125,427	$2,487,664
2019	930	112,731	$2,113,618
2020	805	166,478	$2,409,988
2021	854	173,223	$2,636,287
2022	1,036	174,143	$2,928,706
2023	861	178,662	$2,580,205
2024	923	199,832	$2,752,943

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	722	5,649	$1,650,602
2016	781	5,069	$1,452,184
2017	674	4,040	$1,335,204
2018	651	3,281	$1,460,080
2019	631	2,820	$2,148,935
2020	541	2,096	$1,754,012
2021	469	1,737	$1,002,722
2022	488	1,687	$875,396
2023	443	1,780	$1,092,638
2024	525	2,047	$1,401,753

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	135	135	$125
96413	Administration of chemotherapy into vein, 1 hour or less	184	938	$105
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	550	929	$97
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	357	456	$66
96401	Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle	98	350	$58

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xeljanz Xr	Tofacitinib Citrate	39	1,170	$232,013
Forteo	Teriparatide	33	1,082	$164,142
Enbrel Sureclick	Etanercept	20	560	$147,362
Otezla	Apremilast	21	630	$101,526
Simponi	Golimumab	14	420	$80,373

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	123	$9,071	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	5	$10,234	ABBVIE INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Paul G. Sutej, MD?

Tedicare shows public-source Medicare data for Paul G. Sutej, MD (NPI 1053353052), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Paul G. Sutej, MD have ACO affiliation data?

Paul G. Sutej, MD is shown with ACO affiliation data for Southeastern Health Partners (MSSP, ACO ID A3325) and TC2, LLC (MSSP, ACO ID A3365).

What billing organization is linked to Paul G. Sutej, MD?

Paul G. Sutej, MD is linked to SOUTHEASTERN RHEUMATOLOGY ALLIANCE (billing NPI 1114795663) in the available physician profile data.

Does Paul G. Sutej, MD have Open Payments data?

Paul G. Sutej, MD has 128 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.